PL450187A1 - Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania - Google Patents

Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania

Info

Publication number
PL450187A1
PL450187A1 PL450187A PL45018724A PL450187A1 PL 450187 A1 PL450187 A1 PL 450187A1 PL 450187 A PL450187 A PL 450187A PL 45018724 A PL45018724 A PL 45018724A PL 450187 A1 PL450187 A1 PL 450187A1
Authority
PL
Poland
Prior art keywords
complex
obtaining
micropellet
micropellet containing
subject
Prior art date
Application number
PL450187A
Other languages
English (en)
Inventor
Ewa Wietrak
Original Assignee
Nutropharma Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutropharma Spółka Z Ograniczoną Odpowiedzialnością filed Critical Nutropharma Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL450187A priority Critical patent/PL450187A1/pl
Priority to PCT/PL2025/050067 priority patent/WO2026095821A1/en
Publication of PL450187A1 publication Critical patent/PL450187A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest kompleks zawierający resweratrol i leucynę oraz sposób wytwarzania kompleksu. Przedmiotem zgłoszenia jest również mikropeletka zawierająca powyższy kompleks oraz sposób otrzymywania tej mikropeletki.
PL450187A 2024-10-31 2024-10-31 Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania PL450187A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL450187A PL450187A1 (pl) 2024-10-31 2024-10-31 Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania
PCT/PL2025/050067 WO2026095821A1 (en) 2024-10-31 2025-08-18 A complex, a method of producing the complex, a micropellet comprising the complex, and a method of producing the micropellet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL450187A PL450187A1 (pl) 2024-10-31 2024-10-31 Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania

Publications (1)

Publication Number Publication Date
PL450187A1 true PL450187A1 (pl) 2026-05-04

Family

ID=97445288

Family Applications (1)

Application Number Title Priority Date Filing Date
PL450187A PL450187A1 (pl) 2024-10-31 2024-10-31 Kompleks, sposób otrzymywania kompleksu, mikropeletka zawierająca kompleks i sposób jej otrzymywania

Country Status (2)

Country Link
PL (1) PL450187A1 (pl)
WO (1) WO2026095821A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150066051A (ko) * 2013-12-06 2015-06-16 (주)복슨로하스 칼로리제한모방효과를 갖는 기능성선식
US10568352B1 (en) * 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
CN105228627B (zh) * 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
EP3197437A4 (en) * 2014-09-24 2018-05-23 NuSirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
US20190060336A1 (en) * 2015-10-07 2019-02-28 Joel HUIZENGA Resetting biological pathways for defending against and repairing deterioration from human aging
US20250312369A1 (en) * 2022-05-12 2025-10-09 Wonderfeel Anti-aging and anti-inflammatory compositions comprising nicotinamide mononucleotide and resveratrol and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150066051A (ko) * 2013-12-06 2015-06-16 (주)복슨로하스 칼로리제한모방효과를 갖는 기능성선식
US10568352B1 (en) * 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUCKBAUER A, ZEMEL MB, THORPE T, AKULA MR, STUCKEY AC, OSBORNE D, MARTIN EB, KENNEL S, WALL JS: "Nutr Metab (Lond). 2012 Aug 22;9(1):77. doi: 10.1186/1743-7075-9-77", SYNERGISTIC EFFECTS OF LEUCINE AND RESVERATROL ON INSULIN SENSITIVITY AND FAT METABOLISM IN ADIPOCYTES AND MICE. *
ZHOU H, SHAN Y, TONG F, ZHANG Y, TANG J, SHEN R, CHEN D: "J Biomed Nanotechnol. 2020 Mar 1;16(3):382-389. doi: 10.1166/jbn.2020.2900", RESVERATROL NANOPARTICLE COMPLEX: POTENTIAL THERAPEUTIC APPLICATIONS IN MYOCARDIAL ISCHEMIA REPERFUSION INJURY., DOI: skrót *

Also Published As

Publication number Publication date
WO2026095821A1 (en) 2026-05-07

Similar Documents

Publication Publication Date Title
MX2019014881A (es) Metodo y aparato para generar y usar una se?al de referencia para canal de difusion para un sistema de radio.
MX2021002247A (es) Metodo y aparato de transmision de datos y terminal.
BR112023019767A2 (pt) Métodos realizados por uma primeira função de rede, por uma segunda função de rede, por um equipamento de usuário e por uma função de rede, programa de computador, portador contendo o programa de computador, programa de computador, função de rede, e, primeira e segunda funções de rede
MX2023001857A (es) Método de acceso a canal y aparato de comunicación.
NO20053852L (no) En kjolefremgangsmate og produksjonen av flytende naturgass
ATE339856T1 (de) Vorrichtung für telekommunikationsdienste
BRPI0608958B8 (pt) método para transmissão de dados em um sistema de comunicação e método para transmissão de dados por uma estação de base em um sistema de comunicação
BR112018076434A2 (pt) método de determinação de estação de base de posicionamento, servidor de posicionamento, estação de base de serviço e sistema de rede
MX2021006207A (es) Metodo, aparato y terminal para procesar solicitud de programacion.
MX2019009098A (es) Terminal de usuario y metodo de comunicacion por radio.
MX2022001335A (es) Sincronizacion de recursos de nodos de acceso y retroceso integrados.
MY200992A (en) Camp Receptor Protein Variant and Method of Producing L-Amino Acid using the same
AR111019A1 (es) Sistema y método para sincronizar interacciones de reuniones notariales entre múltiples clientes de software
BR112023001570A2 (pt) Método realizado por um dispositivo de comunicação sem fio, dispositivo de comunicação sem fio, método realizado por uma estação-base, e, estação-base
DE602004011610D1 (de) Web-anwendungsserver
MX2021012296A (es) Microorganismo que produce l-aminoacido y procedimiento de produccion de l-aminoacido mediante el uso del mismo.
BR112023000685A2 (pt) Transição de estado em sistemas de retransmissão da camada 2 de sidelink
BR112023019097A2 (pt) Técnicas de feedback para informação de controle de downlink em um canal compartilhado de downlink físico
ATE406773T1 (de) Funkkommunikation mit ofdma und ifdma
MY206564A (en) Distributed demand generation platform
MX2023012613A (es) Metodo y aparato de comunicacion.
EP4560944A3 (en) Point-to-point database synchronization over a transport protocol
MX2023007621A (es) Metodo para expandir una comunidad compleja de microorganismos.
BR112022003621A2 (pt) Método para produzir uma espuma de poliuretano, espuma de poliuretano, e, método de fabricação de um gabinete termicamente isolado
Alfianto et al. PISANG GEN ALFA: Smartphone Application for Mental Health Families of Alpha Generation in Indonesia